第一财经网·2025-09-21 09:57Core Viewpoint - The incident at Kanglong Chemical resulted in two fatalities and highlighted significant safety issues within the company, prompting regulatory scrutiny and potential penalties [1][4]. Company Summary - Kanglong Chemical is the second-largest pharmaceutical outsourcing company by revenue in the A-share market, with a reported revenue of 6.441 billion yuan in the first half of 2025 [5]. - The company provides integrated drug research, development, and production services, covering the entire process from drug discovery to development [5]. Incident Details - The incident occurred on June 3, 2025, involving two employees who were found unresponsive in a flexible isolator due to a nitrogen gas influx that led to a critical drop in oxygen levels [2]. - The investigation revealed that the employees failed to follow safety protocols, specifically regarding the operation of the flexible isolator [2][3]. Regulatory Actions - The investigation concluded that the incident was a general production safety accident caused by violation of operational procedures [4]. - Ten management personnel from Kanglong Chemical are facing fines of 20% to 50% of their annual income for violations of the Production Safety Law [4]. - The company may also face a fine ranging from 300,000 to 1 million yuan as a result of the incident [5]. Industry Implications - The incident serves as a warning for the pharmaceutical outsourcing industry regarding the importance of safety protocols and risk management [5]. - Regulatory bodies have emphasized the need for comprehensive safety checks and immediate rectification of identified hazards to prevent similar occurrences in the future [5].